Altimmune Inc
NASDAQ:ALT 2:29:47 PM EDT
| Market Cap (Intraday) | 669.51M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $13.96 |
| 50-Day MA | $12.67 |
| 200-Day MA | $11.37 |
Altimmune Inc Stock, NASDAQ:ALT
910 Clopper Road, Suite 201S, Gaithersburg, Maryland 20878
United States of America
Phone: +1.240.654.1450
Number of Employees: 47
Description
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.